Key regions: United States, Europe, Brazil, Japan, United Kingdom
Bronchodilator drugs are widely used in Turkey to treat respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). The market for these drugs has been witnessing steady growth in recent years.
Customer preferences: Bronchodilator drugs are highly preferred by customers in Turkey due to the high prevalence of respiratory diseases in the country. The drugs are available in various forms such as inhalers, tablets, and syrups, which provide convenience to customers in terms of usage.
Trends in the market: The Turkish government has been taking initiatives to improve the healthcare infrastructure in the country, which has led to an increase in the availability and accessibility of bronchodilator drugs. Moreover, the increasing awareness about respiratory diseases and their treatment options has also contributed to the growth of the market.The market is witnessing a shift towards the use of combination bronchodilator drugs, which offer better efficacy and convenience compared to single-component drugs. This trend is expected to continue in the coming years.
Local special circumstances: Turkey has a high prevalence of respiratory diseases, which is attributed to various factors such as air pollution, smoking, and genetic predisposition. The country has a large population of smokers, which increases the risk of respiratory diseases. Moreover, the high levels of air pollution in urban areas also contribute to the prevalence of respiratory diseases.
Underlying macroeconomic factors: The Turkish pharmaceutical market has been growing steadily in recent years, driven by factors such as increasing population, rising income levels, and government initiatives to improve healthcare infrastructure. The market is expected to continue growing in the coming years, which will provide opportunities for bronchodilator drug manufacturers.In conclusion, the bronchodilator drug market in Turkey is witnessing steady growth due to the high prevalence of respiratory diseases, increasing awareness about treatment options, and government initiatives to improve healthcare infrastructure. The market is expected to continue growing in the coming years, driven by factors such as increasing population and rising income levels.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
